

PROVINCIAL FUNDING SUMMARY

Nab paclitaxel (Abraxane) for Metastatic Pancreatic Cancer

pERC Recommendation: Recommends with conditions

For further details, please see [pERC Final Recommendation](#)

Notification to Implement Issued by pCODR: October 8, 2014

This information is current as of April 24, 2015.

Note: Funding criteria as listed on the decision date. Please refer to the provincial drug programs and cancer agencies for the most recent funding criteria and program eligibility.

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
BC	Funded	Nov 1, 2014	<p>Previously untreated locally advanced unresectable or metastatic pancreatic cancer Patients can have received gemcitabine in the adjuvant setting, ECOG 0 to 2, and age 18 to 75 years.</p> <p>A BCCA “Compassionate Access Program” request with appropriate clinical information for each patient must be approved prior to treatment.</p>
AB	Funded	Mar 30, 2015	Nab-paclitaxel plus gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas or patients unable to tolerate FOLFIRINOX. Not to be used after progression on FOLFIRINOX.
SK	Under Provincial Consideration*		
MB	Funded	Apr 20, 2015	Nab-paclitaxel (Abraxane) plus gemcitabine for the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with Karnofsky performance status of 100 to 70 (ECOG performance status 0 to 2) or for patients who are intolerant to first line treatment with FOLFIRINOX

PROVINCE	STATUS	DECISION DATE	FUNDING CRITERIA
ON	Funded	Apr 17, 2015	<ul style="list-style-type: none"> •For the first line treatment of patients with locally advanced unresectable or metastatic adenocarcinoma of the pancreas with ECOG Performance Status of 0 to 2. •Funding for FOLFIRINOX or Abraxane is only permitted ONCE per patient throughout the course of their disease and must be given in the first-line setting. •Gemcitabine alone will continue to be an alternative in the first-line setting and will also be funded in the second line setting after FOLFIRINOX. •A patient’s first-line regimen can be switched (from FOLFIRINOX to Abraxane or vice versa) due to documented toxicity/intolerance issues provided there has been no disease progression and the switch occurs within the first 3 months of initiating the first-line regimen. •On a time limited basis (6 months): Patients with locally advanced unresectable adenocarcinoma of the pancreas who initiated gemcitabine therapy prior to April 17, 2015 in the first-line setting and whose disease has not progressed, will have the option of adding Abraxane to their treatment regimen or switching to FOLFIRINOX. Patients with metastatic adenocarcinoma of the pancreas who initiated gemcitabine therapy prior to April 17, 2015 in the first-line setting and whose disease has not progressed, will have the option of adding Abraxane to their treatment regimen.
NS	Under provincial consideration*		
NB	Under provincial consideration*		
NL	Under provincial consideration*		
PEI	Under provincial consideration*		

*Under provincial consideration means that the province is reviewing pCODR’s recommendation. This may include the province working with the drug manufacturer to reach an agreement for a drug product that both parties can accept, in particular in cases where the pCODR Expert Review Committee has recommended that the drug be funded only on the condition of cost-effectiveness being improved to an acceptable level. This may occur before or after the pan-Canadian Pharmaceutical Alliance negotiations. Please contact the specific provincial drug program and/or cancer agency in your province for information about the status of a given drug product.